中国药理学与毒理学杂志Issue(2)：87-94,8.DOI:10.3867/j.issn.1000-3002.2016.02.001
癌症的免疫治疗和细胞治疗
Immunotherapy and cell therapy for cancer
Jeremy COPP 1谢伟东 2张朝杰 3Jon BERGLIN1
作者信息
- 1. Theragene Pharmaceuticals，Inc. 11555 Sorrento Valley Road，Suite A，San Diego，CA，USA 92121
- 2. Lindan Biotech，Ltd. 4-1250 Waverly Street，Winnipeg，MB，Canada
- 3. 东莞中山大学研究院，广东东莞 523000
- 折叠
摘要
Abstract
Cancer immunotherapies are recently gaining attention as viable therapeutic options. There are two types of immunotherapy:passive and active. The passive immunotherapies include several treatments such as monoclonal antibodies,either alone or as antibody-drug conjugates. The active immunotherapies include cancer vaccines which utilize the patient′s own cells as antigen presenting cells and target specific cancer antigens,and chimeric antigen receptor T-cell(CAR-T)therapy which engineers a patient′s T-cells to recognize cancer antigens through chimeric antigen receptors. Recent successes include the US FDA approval of a number of cancer immunotherapies such as treatments utilizing monoclonal antibodies against immune checkpoint inhibitors,the Provenge cancer vaccine that targets prostrate cancer,and a CAR-T against relapsed/refractory acute lymphoblastic leukemia that was designated with breakthrough drug status,all of which has had drug companies investigating cancer immunotherapies with intense enthusiasm. In this review we discuss where the field of immune-oncology stands today,highlight the latest findings and hypothesize future directions.关键词
癌症/免疫治疗/被动免疫治疗/主动免疫治疗/癌症疫苗/嵌合抗原受体T细胞(CAR-T)Key words
cancer/immunotherapy/passive immunotherapy/active immunotherapy/cancer vaccine/chimeric antigen receptor T-cell(CAR-T)分类
医药卫生引用本文复制引用
Jeremy COPP,谢伟东,张朝杰,Jon BERGLIN..癌症的免疫治疗和细胞治疗[J].中国药理学与毒理学杂志,2016,(2):87-94,8.
